Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
Search Article 
Advanced search 
  Users Online: 37 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

Table of Contents
Year : 2013  |  Volume : 17  |  Issue : 5  |  Page : 775-779

Adaptation to vitamin D deficiency: Age specific clinical presentations

1 Department of Pediatrics and Endocrinology, Hamad Medical Center, Doha, Qatar, India
2 Department of Endocrinology, Bharti Hospital and B.R.I.D.E, Karnal, India

Date of Web Publication29-Aug-2013

Correspondence Address:
Ashraf Soliman
Pediatrics and Endocrinology, Hamad Medical Center, Doha, Qatar
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2230-8210.117185

Rights and Permissions

How to cite this article:
Soliman A, Kalra S. Adaptation to vitamin D deficiency: Age specific clinical presentations. Indian J Endocr Metab 2013;17:775-9

How to cite this URL:
Soliman A, Kalra S. Adaptation to vitamin D deficiency: Age specific clinical presentations. Indian J Endocr Metab [serial online] 2013 [cited 2021 May 14];17:775-9. Available from: https://www.ijem.in/text.asp?2013/17/5/775/117185

Vitamin D (VD) seems to have taken center stage in not only endocrine, but all medical, literature, in recent years. An enhanced understanding of the extra-skeletal actions of VD, elucidation of its autocrine and paracrine effects, and the heliophobic life-style followed by many cultures, such as in the Middle East and South Asia, have contributed to this. At the same time; however, the classic antirachitic effects of VD so important for growth in children, seem to have been neglected. This editorial highlights the age specific clinical presentations, including subtle symptoms and signs, noted in different pediatric age groups, and correlates this with the adaptive response to VD deficiency.

VD is critical for calcium (Ca) homeostasis and for mineralization of the skeleton, especially during periods of rapid growth, namely infantile and pubertal growth periods. Vitamin D deficiency (VDD) leads to rickets (a mineralization defect at the epiphyseal growth plates and bone tissue) and osteomalacia (a mineralization defect of bone tissue). [1]

The development of clinical manifestations of VDD rickets is dependent on many factors apart from the severity and duration of the VDD (circulating concentrations of 25-hydroxy vitamin D [25-OH-D]) [Table 1]. A potent adaptation process, mediated by parathormone (PTH) and insulin-like growth factor-I (IGF-I), [2],[3],[4],[5],[6],[7],[8],[9]1 modifies the clinical and radiological manifestations of VDD. Therefore, overt cases of rickets and osteomalcia represent only the tip of the iceberg of patients with severe VDD and malfunction of adaptation. [2],[10],[11] It is noteworthy that when clinical rickets develops, the entire process occurs rapidly, within a few months. [12]
Table 1: Factors influencing clinical presentation of VDD

Click here to view

   Physiologic Adaptation Top

Without VD, only 10-15% of dietary Ca and about 60% of phosphorus is absorbed. The active form, 1,25-dihydroxy vitamin D (1,25-(OH) 2D3) markedly increases the efficiency of intestinal Ca and phosphorus absorption. [2],[3],[4],[5],[6] Serum levels below 30 ng/ml are associated with a significant decrease in intestinal Ca absorption. In children, adolescents, and adults; this is associated with increased PTH and deceased IGF-I secretion. Serum levels of 25-OH-D are directly related to bone mineral density with a maximum density achieved when the 25-OH-D level reached 40 ng/ml or more. [2],[3],[4],[5],[6],[7],[8]

PTH enhances the tubular reabsorption of Ca and stimulates the kidneys to produce 1,25-(OH) 2D3. [3],[4],[5],[6] It also activates osteoblasts, which stimulate the transformation of preosteoclasts into mature osteoclasts. [3],[4],[5],[6] Osteoclasts dissolve the mineralized collagen matrix in bone, causing osteopenia and osteoporosis [12],[13],[14],[15] and provide enough Ca to prevent hypocalcemia.

There is a bidirectional link between IGF-I and VD, which is played out in different forms at the systemic (circulating) and the local (growth plate) level. Systemically, IGF-I stimulates the production of 1,25-(OH) 2D3 by kidney cells independently of growth hormone (GH). [16],[17],[18],[19] IGF-I stimulates bone formation, even in absence of GH, through an intrinsic action on osteoblasts. It supports proliferation, differentiation and matrix synthesis in cultures of osteoblast-like cells and bone organ cultures. It potently stimulates the production of type I collagen (the main structural protein of bone) and increases pro-collagenα1 (I) mRNA expression both in osteoblasts in vitro and in bone in vivo.[20],[21],[22] Lack of IGF-I, therefore, may impact skeletal health adversely.

Locally in the growth plate, 1,25-(OH) 2D3 potentiates local IGF-I synthesis in chondrocytes and stimulates cell proliferation and differentiation as judged by increased alkaline phosphatase (ALP) activity, collagen X mRNA, and matrix calcification in long-term experiments. 1,25-(OH) 2D3 stimulates chondrocytes proliferation and cell differentiation. [23] In rats infusion of GH or IGF-I shortens stem and proliferating cell cycle time in the growth plate of hypophysectomized rats and decreases the duration of the hypertrophic differentiation phase. [24]

   Pathophysiologic Adaptation in VDD Top

Consequently, during VDD decreased circulating and locally produced IGF-I in children appears to be a gradual adaptive process to inhibit linear growth (in growth plate) and bone mineral accretion (diaphysis). This process conserves bone minerals and proteins to maintain normal serum Ca concentration and slows down the breakdown of the already formed bones instead of consuming them in forming new bones. In addition, decreased circulating and locally produced IGF-I concentrations can explain in part the defective matrix calcification. The irregular maturation of chondrocytes, and the large irregular hypertrophic zone found in the growth plate of rachitic children can be explained by the prolongation of the cell cycle time, defective maturation, and impaired calcification due to the effect of high level of PTH (stimulates proliferation of chondrocytes) in the presence of low IGF-I (delays maturation and calcification of chondrocytes). In addition, low IGF-I may also allow the catabolic effect of PTH necessary for effective release of Ca and explains the osteoporotic appearance of the diaphysis in rachitic children. [2],[22],[23],[24],[25]

   Clinical Rickets in Children Top

Only a small number of infants, toddlers, adolescents, and adults with VDD develop clinical manifestations of rickets or osteomalacia, depending on the severity, duration, and adaptive responses of VDD. [2],[10],[11],[26]

The typical clinical picture of rickets in children includes, growth plate abnormalities and delayed growth, weakening and bowing of weight-bearing bones, hypoplasia of tooth enamel, and hypocalcemia with muscle hypotonia and even tetany. [2],[3],[4],[5],[6],[9] The basic skeletal lesion is impaired mineralization of the matrix produced by growth-plate chondrocytes or osteoblasts. This zone is characterized by flaring of the ends of the bones and the "rachitic rosary." This entire process occurs within a few months. [2],[3],[4],[5],[12]

   Hierarchy of Abnormalities Top

In infants and toddlers, three sequential clinical (biochemical-hormonal-radiological) stages have been described [Table 2]. [2]
Table 2: Hierarchy of abnormalities in rickets

Click here to view

The influence of adaptive mechanisms, mediated by PTH and IGF-I, can easily be noticed in the various stages of VDD. Radiological and biochemical abnormalities correspond well to hormonal changes noticed with VDD.

An analysis of growth with biochemical and radiological data of rachitic patients presenting with hypocalcemia (dysadapted) versus those with normocalcemia (adapted) supported this concept of adaptation [Table 2].

   Growth Impairment in Rickets Top

Rickets is associated with growth impairment in infants and young children. Many factors contribute to impaired linear growth in these children with VDD [Table 3]. Marked improvement of linear growth with complete catch-up growth has been shown with proper treatment with VD. [5],[10],[13],[22],[23],[24],[25],[26],[27],[28],[29]
Table 3: Factors contributing to growth retardation in rickets

Click here to view

   Clinical Rickets in Adolescents Top

In adolescents, presentation of severe and/or prolonged VDD markedly differs from young children. They present with vague manifestations including pain in weight bearing joints, back, thighs and/or calves, difficulty in walking and/or climbing stairs and/or running, muscle cramps, facial twitches and carpo-pedal spasms. Compared to children with VDD, adolescents have higher serum Ca, PO 4 and IGF-I concentration and lower PTH and ALP concentrations. Radiological changes are less frequent and less significant compared to children with rickets. These data denote better adaptation to VDD in adolescents compared with young children. This better adaptation in adolescents can be explained by their relatively larger bone mass (Ca and PO 4 stores) and lower requirement for Ca and PO 4 /kg, due to relatively slower growth rate compared with infants and young children. [30],[31]

Two different radiological patterns of severe VDD in adolescents have been detected. Pattern (I), with localized metaphyseal multilocular cystic lesions, occur in overweight adolescents with good intake of milk/milk products. Adolescents with pattern (I) appear to have better adaptation to VDD because of maintaining near-normal bone architecture of the cortex of long bones (better bone mass) and having higher serum PO 4 concentrations and absence of hypocalcemia episodes. Whereas pattern (II), with generalized diminished bone density, occurs in adolescents with relatively lower body mass index (BMI) (<18), with no or poor intake of milk and lower IGF-I versus those with pattern (I). The higher fat mass (BMI >25), IGF-I concentrations and consumption of milk (better Ca and phosphate intake) support better adaptation in adolescents with pattern (I). All these three factors have been shown to maintain bone density in children and adolescents. [30],[31],[32],[33],[34],[35],[36]

   Clinical Rickets in Newborns Top

In newborns, the clinical and radiological manifestations of severe VDD newborns are scantily described. Deficient maternal VD status has been shown to be associated with lower birth weight, higher small for gestational age (SGA) risk and altered neonatal growth, both in weight and in length. Severe VDD in newborns usually present with hypocalcemia and hypocalcemic symptoms (dysadaption) including seizures; without significant rachitic changes apart from craniotabes. Radiologically minimal or no changes have been describes despite decreased mineralization detected by bone density scan. The poor adaptation of newborns to VDD, compared to older infants and toddlers, can be explained by their lower PTH secretion in response to hypocalcemia, decreased skeletal response to PTH, and decreased bone mass. [37],[38],[39],[40],[41],[42]

   Conclusion Top

In summary, clinical presentation of severe VDD markedly differs during the different stages of growth. Newborns appear to be less adapted whereas adolescents are better adapted to VDD. Pediatricians and physicians have to be aware about the variability of these different clinical presentations for proper diagnosis and management. While the concern of physicians about VDD in adults is mainly focused on the extra-skeletal manifestations, endocrinologists must not neglect the core biological skeletal effects of VDD, in the pediatric age group, the ones who need it the most.


1It is well appreciated that overt cases of rickets represent only the tip of the iceberg of infants and children with VDD. [30],[31]

   References Top

1.Root AW, Diamond FB. Calcium metabolism, normal homeostasis and disorders of calcium metabolism in the child and adolescent. In: Sperling MA, editor. Pediatric Endocrinology. 2 nd ed. Philadelphia: Saunders; 2002. p. 65-110.  Back to cited text no. 1
2.Soliman AT, Al Khalaf F, Alhemaidi N, Al Ali M, Al Zyoud M, Yakoot K. Linear growth in relation to the circulating concentrations of insulin-like growth factor I, parathyroid hormone, and 25-hydroxy vitamin D in children with nutritional rickets before and after treatment: Endocrine adaptation to vitamin D deficiency. Metabolism 2008;57:95-102.  Back to cited text no. 2
3.Holick MF. Resurrection of vitamin D deficiency and rickets. J Clin Invest 2006;116:2062-72.  Back to cited text no. 3
4.Holick MF, Garabedian M. Vitamin D: Photobiology, metabolism, mechanism of action, and clinical applications. In: Favus MJ, editor. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 6 th ed. Washington, DC: American Society for Bone and Mineral Research; 2006. p. 129-37.  Back to cited text no. 4
5.Bouillon R. Vitamin D: From photosynthesis, metabolism, and action to clinical applications. In: DeGroot LJ, Jameson JL, editors. Endocrinology. Philadelphia: W.B. Saunders; 2001. p. 1009-28.  Back to cited text no. 5
6.DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004;80 (6 Suppl):1689S-96S.  Back to cited text no. 6
7.Heaney RP, Dowell MS, Hale CA, Bendich A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 2003;22:142-6.  Back to cited text no. 7
8.Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006;84:18-28. [Erratum. Am J Clin Nutr 2006;84:1253].  Back to cited text no. 8
9.Pettifor JM. Rickets and vitamin D deficiency in children and adolescents. Endocrinol Metab Clin North Am 2005;34:537-53, vii.  Back to cited text no. 9
10.Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: Consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001;22:477-501.  Back to cited text no. 10
11.Boonen S, Bischoff-Ferrari HA, Cooper C, Lips P, Ljunggren O, Meunier PJ, et al. Addressing the musculoskeletal components of fracture risk with calcium and vitamin D: A review of the evidence. Calcif Tissue Int 2006;78:257-70.  Back to cited text no. 11
12.Bakhtiyarova S, Lesnyak O, Kyznesova N, Blankenstein MA, Lips P. Vitamin D status among patients with hip fracture and elderly control subjects in Yekaterinburg, Russia. Osteoporos Int 2006;17:441-6.  Back to cited text no. 12
13.McKenna MJ. Differences in vitamin D status between countries in young adults and the elderly. Am J Med 1992;93:69-77.  Back to cited text no. 13
14.Bianda T, Glatz Y, Bouillon R, Froesch ER, Schmid C. Effects of short-term insulin-like growth factor-I (IGF-I) or growth hormone (GH) treatment on bone metabolism and on production of 1,25-dihydroxycholecalciferol in GH-deficient adults. J Clin Endocrinol Metab 1998;83:81-7.  Back to cited text no. 14
15.Condamine L, Menaa C, Vrtovsnik F, Friedlander G, Garabédian M. Local action of phosphate depletion and insulin-like growth factor 1 on in vitro production of 1,25-dihydroxyvitamin D by cultured mammalian kidney cells. J Clin Invest 1994;94:1673-9.  Back to cited text no. 15
16.Wright NM, Papadea N, Wentz B, Hollis B, Willi S, Bell NH. Increased serum 1,25-dihydroxyvitamin D after growth hormone administration is not parathyroid hormone-mediated. Calcif Tissue Int 1997;61:101-3.  Back to cited text no. 16
17.Hock JM, Centrella M, Canalis E. Insulin-like growth factor I has independent effects on bone matrix formation and cell replication. Endocrinology 1988;122:254-60.  Back to cited text no. 17
18.Schmid C, Ernst M, Binz K, Zapf J, Froesch ER. The endocrine/paracrine actions of IGFs on bone. In: Spencer EM, editor. Proceedings of the Second International Symposium of Insulin-like Growth Factors. New York: Elsevier; 1991. p. 591-605.  Back to cited text no. 18
19.Tanaka H, Quarto R, Williams S, Barnes J, Liang CT. In vivo and in vitro effects of insulin-like growth factor-I (IGF-I) on femoral mRNA expression in old rats. Bone 1994;15:647-53.  Back to cited text no. 19
20.Krohn K, Haffner D, Hügel U, Himmele R, Klaus G, Mehls O, et al. 1,25(OH) 2D3 and dihydrotestosterone interact to regulate proliferation and differentiation of epiphyseal chondrocytes. Calcif Tissue Int 2003;73:400-10.  Back to cited text no. 20
21.Robson H, Siebler T, Shalet SM, Williams GR. Interactions between GH, IGF-I, glucocorticoids, and thyroid hormones during skeletal growth. Pediatr Res 2002;52:137-47.  Back to cited text no. 21
22.Yonemura K, Fujimoto T, Fujigaki Y, Hishida A. Vitamin D deficiency is implicated in reduced serum albumin concentrations in patients with end-stage renal disease. Am J Kidney Dis 2000;36:337-44.  Back to cited text no. 22
23.Klaus G, Weber L, Rodríguez J, Fernández P, Klein T, Grulich-Henn J, et al. Interaction of IGF-I and 1 alpha, 25(OH) 2D3 on receptor expression and growth stimulation in rat growth plate chondrocytes. Kidney Int 1998;53:1152-61.  Back to cited text no. 23
24.Lund B, Charles P, Egsmose C, Lund B, Melsen F, Mosekilde L, et al. Changes in vitamin D metabolites and bone histology in rats during recovery from rickets. Calcif Tissue Int 1985;37:478-83.  Back to cited text no. 24
25.Hatun S, Islam O, Cizmecioglu F, Kara B, Babaoglu K, Berk F, et al. Subclinical vitamin D deficiency is increased in adolescent girls who wear concealing clothing. J Nutr 2005;135:218-22.  Back to cited text no. 25
26.Ladhani S, Srinivasan L, Buchanan C, Allgrove J. Presentation of vitamin D deficiency. Arch Dis Child 2004;89:781-4.  Back to cited text no. 26
27.Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997;350:550-5.  Back to cited text no. 27
28.Reeve J, Bradbeer JN, Arlot M, Davies UM, Green JR, Hampton L, et al. hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: Biochemical, kinetic and histological responses. Osteoporos Int 1991;1:162-70.  Back to cited text no. 28
29.Soliman AT, El-Dabbagh M, Adel A, Al Ali M, Aziz Bedair EM, Elalaily RK. Clinical responses to a mega-dose of vitamin D3 in infants and toddlers with vitamin D deficiency rickets. J Trop Pediatr 2010;56:19-26.  Back to cited text no. 29
30.Soliman AT, Adel A, Wagdy M, Alali M, Aziz Bedair EM. Manifestations of severe vitamin D deficiency in adolescents: Effects of intramuscular injection of a megadose of cholecalciferol. J Trop Pediatr 2011;57:303-6.  Back to cited text no. 30
31.Mølgaard C, Thomsen BL, Prentice A, Cole TJ, Michaelsen KF. Whole body bone mineral content in healthy children and adolescents. Arch Dis Child 1997;76:9-15.  Back to cited text no. 31
32.Soliman A, De Sanctis V, Adel A, El Awwa A, Bedair S. Clinical, biochemical and radiological manifestations of severe vitamin D deficiency in adolescents versus children: Response to therapy. Georgian Med News 2012;210:58-64.  Back to cited text no. 32
33.Rodríguez Martínez G, Blay G, Blay VA, Moreno LA, Bueno M. Association of fat mass with bone mineral content in female adolescents. Obes Res 2002;10:715.  Back to cited text no. 33
34.Yasunaga T, Furukawa S, Katsumata N, Horikawa R, Tanaka T, Tanae A, et al. Nutrition related hormonal changes in obese children. Endocr J 1998;45:221-7.  Back to cited text no. 34
35.Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 2008;29:535-59.  Back to cited text no. 35
36.Ruiz JC, Mandel C, Garabedian M. Influence of spontaneous calcium intake and physical exercise on the vertebral and femoral bone mineral density of children and adolescents. J Bone Miner Res 1995;10:675-82.  Back to cited text no. 36
37.Namgung R, Tsang RC. Bone in the pregnant mother and newborn at birth. Clin Chim Acta 2003;333:1-11.  Back to cited text no. 37
38.Javaid MK, Crozier SR, Harvey NC, Gale CR, Dennison EM, Boucher BJ, et al. Maternal vitamin D status during pregnancy and childhood bone mass at age 9 years: A longitudinal study. Lancet 2006;367:36-43.  Back to cited text no. 38
39.Yorifuji J, Yorifuji T, Tachibana K, Nagai S, Kawai M, Momoi T, et al. Craniotabes in normal newborns: The earliest sign of subclinical vitamin D deficiency. J Clin Endocrinol Metab 2008;93:1784-8.  Back to cited text no. 39
40.Leffelaar ER, Vrijkotte TG, van Eijsden M. Maternal early pregnancy vitamin D status in relation to fetal and neonatal growth: Results of the multi-ethnic Amsterdam born children and their development cohort. Br J Nutr 2010;104:108-17.  Back to cited text no. 40
41.Specker BL. Does vitamin D during pregnancy impact offspring growth and bone? Proc Nutr Soc 2012;71:38-45.  Back to cited text no. 41
42.Viljakainen HT, Saarnio E, Hytinantti T, Miettinen M, Surcel H, Mäkitie O, et al. Maternal vitamin D status determines bone variables in the newborn. J Clin Endocrinol Metab 2010;95:1749-57.  Back to cited text no. 42


  [Table 1], [Table 2], [Table 3]

This article has been cited by
1 Vitamin D status in prepubertal children with isolated idiopathic growth hormone deficiency: effect of growth hormone therapy
Rasha Tarif Hamza,Amira I Hamed,Mahmoud T Sallam
Journal of Investigative Medicine. 2018; 66(5): 1.2
[Pubmed] | [DOI]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
    Physiologic Adap...
    Clinical Rickets...
    Hierarchy of Abn...
    Growth Impairmen...
    Clinical Rickets...
    Clinical Rickets...
    Article Tables

 Article Access Statistics
    PDF Downloaded441    
    Comments [Add]    
    Cited by others 1    

Recommend this journal